Abstract:INTRODUCTION AND OBJECTIVES: Docetaxel (DTX) is one of the primary drugs used for treating castration resistant prostate cancer (CRPC).Unfortunately, over time patients invariably develop resistance to DTX therapy and their disease will continue to progress.The mechanisms by which resistance develops is still incompletely understood.This study seeks to determine the involvement of miRNAs, specifically miR-181a, in DTX resistance in CRPC.METHODS: Total RNA from parental C4-2B prostate cancer cells and DTX resistant C4-2B cells (C4-2B TaxR) was submitted for small RNA deep sequencing.Data was analyzed to ascertain which miRNAs expressions were most altered in C4-2B TaxR cells compared to parental cells.Having identified an increase in miR-181a in resistant cells, its expression was modulated in C4-2B and C4-2B TaxR cells by transfecting them with miR-181a mimics or antisense, respectively.Following transfection, cell number was determined after 48 h with or without DTX.Cross resistance to cabazitaxel induced by miR-181a was also determined.Western blots were used to determine ABCB1 protein expression and rhodamine assays used to assess activity.Phospho-p53 expression was assessed by western blot and apoptosis was measured by ELISA in C4-2B TaxR cells with inhibited miR-181a expression with or without DTX.RESULTS: miR-181a is significantly upregulated in C4-2B TaxR cells compared to parental C4-2B cells as analyzed by small RNA sequencing.Overexpression of miR-181a in C4-2B cells confers DTX and cabazitaxel resistance.Knockdown of miR-181a in C4-2B TaxR cells re-sensitizes them to treatment with both DTX and cabazitaxel.miR-181a knockdown alone induced apoptosis in C4-2B TaxR cells which is further enhanced by DTX.We next assessed if miR-181a altered expression or activity of ABCB1, which is overexpressed/active in C4-2B TaxR cells and promotes resistance to DTX by pumping the drug out of cells.We found that miR-181a does not impact ABCB1 expression or activity.Since we previously demonstrated that phospho-p53 can modulate DTX sensitivity, we determined if miR-181a can alter p53 expression in C4-2B TaxR cells.Knockdown of miR-181a in C4-2B TaxR cells induced phospho-p53 expression, suggesting that miR-181a induced resistance to DTX is mediated by inhibition of phospho-p53 expression.CONCLUSIONS: Overexpression of mir-181a in C4-2B TaxR cells contributes to their resistance to DTX and inhibition of mir-181a expression can restore treatment response.This is due, in part, to modulation of p53 phosphorylation and induction of apoptosis.

MicroRNA-195 Regulates Docetaxel Resistance by Targeting Clusterin in Prostate Cancer

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer

MicroRNA-452 Contributes to the Docetaxel Resistance of Breast Cancer Cells

Secreted miR-210-3p, miR-183-5p and miR-96-5p reduce sensitivity to docetaxel in prostate cancer cells

LncRNA LINC00184 promotes docetaxel resistance and immune escape via miR-105-5p/PD-L1 axis in prostate cancer

Mir-375 is Upregulated in Acquired Paclitaxel Resistance in Cervical Cancer

Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells

Silencing of LINC01963 enhances the chemosensitivity of prostate cancer cells to docetaxel by targeting the miR-216b-5p/TrkB axis

Use of Mir-145 and Testicular Nuclear Receptor 4 Inhibition to Reduce Chemoresistance to Docetaxel in Prostate Cancer

MiR-138–5p Inhibits Prostate Cancer Cell Proliferation and Chemoresistance by Targeting APOBEC3B

MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells Via Direct Suppression of JAG1/Notch1 Axis

miR-1205/DNAJB1 reverses docetaxel chemoresistance in human triple negative breast carcinoma cells via regulation of mutp53/TAp63 signaling

Microrna-137 Inhibits Tumor Growth And Sensitizes Chemosensitivity To Paclitaxel And Cisplatin In Lung Cancer

Identification of Microrna Profiles in Docetaxel-Resistant Human Non-Small Cell Lung Carcinoma Cells (SPC-A1)

The role of miR-222 and miR-298 in breast cancer drug resistance

Overexpression of secretory clusterin (sCLU) induces chemotherapy resistance in human gastric cancer cells by targeting miR-195-5p

Mir-200Bc/429 Cluster Modulates Multidrug Resistance of Human Cancer Cell Lines by Targeting BCL2 and XIAP.

MicroRNA-195-5p, a New Regulator of Fra-1, Suppresses the Migration and Invasion of Prostate Cancer Cells

The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin

MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3.

MP99-17 CIRCULARRNA-C17 ALTERS THE ANTI ANDROGEN-ENZALUTAMIDE RESISTANCE IN CASTRATION-RESISTANT PROSTATE CANCER VIA REGULATING ANDROGEN RECEPTOR VARIANT ARV7 EXPRESSION